Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

Thymoma with Concomitant Pure Red Cell Aplasia, Good’s Syndrome and Myasthenia Gravis Responding to Rituximab

Authors: Ahmad I. Antar, Zaher K. Otrock, Mohamed A. Kharfan-Dabaja, Rami A. Mahfouz, Raafat S. Alameddine, Nadim M. W. El-Majzoub, Ziad M. Salem

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Abstract

Thymomas are often associated with a variety of autoimmune diseases, mostly myasthenia gravis. The association of thymomas with both pure red cell aplasia (PRCA) and Good’s syndrome is exceedingly rare. To the best of our knowledge, the combination of a thymoma with manifestations of myasthenia gravis, PRCA, and Good’s syndrome, as in our case herein, has not been described before in the medical literature. We present a 90-year-old man initially diagnosed with an asymptomatic thymoma. Later, he developed generalized muscle weakness and was found to have severe anemia. He was diagnosed with PRCA, myasthenia gravis and Good’s syndrome. He responded to rituximab with restoration of bone marrow erythroid maturation and stabilization of red blood cell counts.
Literature
1.
Rosai J, Sobin LH (1999) Histological typing of tumours of the thymus. Springer, New York, p 1–16
2.
Kondo K, Yoshizawa K, Tsuyuguchi M, Kimura S, Sumitomo M, Morita J, Miyoshi T, Sakiyama S, Mukai K, Monden Y (2004) WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 77:1183–1188CrossRefPubMed
3.
4.
5.
Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Müller-Hermelink HK, Marx A (2000) Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 96:3872–3879PubMed
6.
Lin CS, Yu YB, Hsu HS, Chou TY, Hsu WH, Huang BS (2009) Pure red cell aplasia and hypogammaglobulinemia in a patient with thymoma. J Chin Med Assoc 72:34–38CrossRefPubMed
7.
Chen J, Yang Y, Zhu D, Chen G, Wei S, Qiu X, Zhou Q (2011) Thymoma with pure red cell aplasia and Good’s syndrome. Ann Thorac Surg 91:1620–1622CrossRefPubMed
8.
van der Marel J, Pahlplatz PV, Steup WH, Hendriks ER (2007) Thymoma with paraneoplastic syndromes, Good’s syndrome, and pure red cell aplasia. J Thorac Oncol 2:325–326CrossRefPubMed
9.
Shiraishi J, Tsugata M, Masuda R, Mori Y, Suzuki K, Takemura T (2008) Type AB thymoma accompanied by pure red cell aplasia and Good syndrome with CMV infection of tumor cells. Pathol Int 58:489–493CrossRefPubMed
10.
Zeok JV, Todd EP, Dillon M, DeSimone P, Utley JR (1979) The role of thymectomy in red cell aplasia. Ann Thorac Surg 28:257–260CrossRefPubMed
11.
12.
Mamiya S, Itoh T, Miura AB (1997) Acquired pure red cell aplasia in Japan. Eur J Haematol 59:199–205CrossRefPubMed
13.
Thompson CA, Steensma DP (2006) Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol 135:405–407CrossRefPubMed
14.
Garcia Vela JA, Monteserin MC, Ona F, Barea LM, Lastra A, Perez V (1993) Cyclosporine A used as a single drug in the treatment of pure red cell aplasia associated with thymoma. Am J Hematol 42:238–239CrossRefPubMed
15.
Pantelidou D, Tsatalas C, Margaritis D, Kaloutsi V, Spanoudakis E, Bourikas G (2004) Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia. Hematol J 5:546–547CrossRefPubMed
16.
Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR (2006) Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res 30:109–114CrossRefPubMed
17.
Dungarwalla M, Marsh JC, Tooze JA, Lucas G, Ouwehand W, Pettengell R, Dearden CE, Gordon Smith EC, Elebute MO (2007) Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol 86:191–197CrossRefPubMed
Metadata
Title
Thymoma with Concomitant Pure Red Cell Aplasia, Good’s Syndrome and Myasthenia Gravis Responding to Rituximab
Authors
Ahmad I. Antar
Zaher K. Otrock
Mohamed A. Kharfan-Dabaja
Rami A. Mahfouz
Raafat S. Alameddine
Nadim M. W. El-Majzoub
Ziad M. Salem
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0478-x

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue

Case Report

All-Trans-Retinoic-Acid Unmasking Hypercalcemia of Hyperparathyroidism

Case Report

Atypical Presentation of Acute Lymphoblastic Leukemia in a 7 Year Old Child

Case Report

Immunoglobulin M ‘Flare’ Seen in a Case of Waldenstrom’s Macroglobulinemia: Successfully Managed by Therapeutic Plasma Exchange

Case Report

Pulmonary Hypertension and Pulmonary Aspergilloma-Coexistence of Two Rare Sequelae of Pulmonary Embolism

Correspondence

Neutrophil Erythrocyte Rosettes: An Unusual Manifestation of Autoimmune Hemolytic Anemia

Case Report

Bilateral Facial Nerve Palsy in Acute B Cell Lymphoblastic Leukemia: A Case Report and Review of the Literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits